The image shows the artistic representation of a new therapy proposed by researcher Xin Gang and his team to combat solid tumors. The proposal combines Adoptive Cell Transfer (ACT) with a pathogen-based cancer vaccine. The therapy called Renergized ACT or ReACT represents an innovative strategy. ReACT therapy uses pathogens to break immunosuppression (decreased response of the body's defense system or immune system) and direct the expansion and migration of tumor-specific T cells to the tumor's location. In a paper published this week in the journal Proceedings of National Academy of Science, PNAS, ReACT therapy improves antitumor efficacy versus common ACT treatments or separate pathogen-based vaccines in eradicating the primary tumor. But it also offers long-term protection against recurrence in preclinical cancer models.
Credit image Lin Zhang (Studio OY Design Consultancy, United Kingdom)References
- Xin, G., Schauder, D. M., Jing, W., Jiang, A., Joshi, N. S., Johnson, B., & Cui, W. (2017). Pathogen boosted adoptive cell transfer immunotherapy to treat solid tumors. Proceedings of the National Academy of Sciences, 201614315